PB-04 Induces HbF Expression in a Ph1b Trial in Sickle Cell Disease

Susan P. Perrine(Center for Drug Evaluation and Research), Patrick C. Hines, Abdullah Kutlar(Augusta University), Mehdi Nouraie(University of Pittsburgh), Kevin H.M. Kuo(University Health Network), Lanetta Bronté-Hall(Institute for Myeloma & Bone Cancer Research), Sylvia Singer(Universidad Católica de Santa Fe), Gershwin T. Blyden, Frans A. Kuypers(Children's Hospital Central California), Aliya U. Zaidi, Aidan Faller(Phoenicia Biosciences (United States))
Journal of sickle cell disease.
June 1, 2024
10.1093/jscdis/yoae002.017
Cited by 1

Related Papers

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study
|Human Molecular Genetics|2011|175
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
|Nature Medicine|2006|162